# Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

> **NCT00629499** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 63 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab paclitaxel
- **DRUG:** Cyclophosphamide
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00629499
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-10
- **Final completion:** 2010-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629499, "Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00629499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*